A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
01/06/2021at 15:15

Pentax forms Chinese partnership for single-use scopes

Japanese medtech giant Pentax and Jiangsu Vedkang are teaming up in a new joint venture company to develop and sell single-use scopes on the European and Asian markets.
BY ALBERT RØNNING ANDERSSON, TRANSLATED BY CATHERINE BRETT

A few days after announcing that it has obtained the CE marking for its single-use bronchoscope Pulmoone, Pentax has more news to share.

The company, which is the second-largest producer of reusable scopes, is starting a new firm to develop and sell these products on the European, South American and Asian markets.

It is doing this alongside Jiangsu Vedkang, which is based in China. The joint venture company has not yet been named and will offer "innovative single-use products to global clients," Pentax reports in a press release.

The company will do this through Pentax's sales network, strengthened by Vedkang's "exceptionally reliable and quality-focused production and research and development infrastructure," Pentax states, and the new firm will be based in China.

Cheaper production in China

The press release does not state which specific products the new company will promote, but Carnegie analyst Niels Granholm-Leth thinks that Pulmoone is an obvious guess.

"I think that Vedkang will produce Pentax's new Pulmoone product and its future single-use endoscopes. It is a bit like the arrangement between Olympus and Vathin – Vathin produces Olympus' single use scope because Chinese production is cheaper," he says.

At the beginning of May, Olympus announced the launch of a new portfolio of five premium single-use scopes for airway examination.

Boston Scientific quickly followed suit with its own single-use bronchoscope, Exalt, after obtaining CE Marking for it at the end of May.

I think that Vedkang will produce Pentax's new Pulmoone product and its future single-use endoscopes

Niels Granholm-Leth, analyst at Carnegie

Ambu has dominated the endoscope market for years, but the competition is heating up. Several of the players who produce reusable scopes are moving into the single-use area.

Ambitions are high – in May, Hiroshi Suziki, the CEO of Pentax's parent company Hoya Corporation, said that it plans to take over 20 percent of the single-use bronchoscope market.

Verathon and Karl Storz have also launched new products for airway examination.

Ambu faces challengers

Ambu is keeping a cool head over the growing competition, as the company expects the market for single-use scopes to grow.

Granholm-Leth has no doubt that the competition within the market is rapidly heating up.

"On the one hand, it will probably acellerate the transition to single-use scopes. On the other hand, it will of course create a battle for market shares. It will be exciting to see if manufacturers can maintain their current prices," he says.

The new players based in China offer significantly lower prices, while Boston Scientific's scopes are more expensive than Ambu's. Within bronchoscopy, the market has already transitioned to 30 percent single-use scopes.

However, the question is how much this will cost. Overall, I think Ambu has a strong position within bronchoscopes and ENT, but it will be a fight to establish a long-term frontrunner position within urology and gastro

Niels Granholm-Leth, analyst at Carnegie

"Within the ear, nose and throat sector (ENT), and urology, the transition has just started. Within the large gastro sector, it hasn't begun yet, and many doctors are still in doubt over the need for single-use products here," Graholm-Leth says.

Some hospitals have also begun to set requirements for the producers of single-use devices to accept them back after use to melt them down.

"A few hospitals in England have gone back to reusable scopes because of environmental concerns, but the manufacturers are working on a collection system," the analyst says.

"However, the question is how much this will cost. Overall, I think Ambu has a strong position within bronchoscopes and ENT, but it will be a fight to establish a long-term frontrunner position within urology and gastro," he adds.

Pentax obtains EU approval for single-use scope

Tough competition forces innovation at Ambu

Olympus launches line of single-use scopes 

Related articles:

  • Pentax CEO Fumio Urano and Hoya Corporation CEO Hiroshi Suziki shake hands

    Pentax obtains EU approval for single-use scope

    For subscribers

  • Juan Jose Gonzalez, CEO of Ambu | Photo: Ambu/PR

    Tough competition forces innovation at Ambu

    For subscribers

  • Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

    Olympus launches line of single-use scopes

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Photo: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Application Manager

  • Head of International Sales

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Principal Laboratory Technologist

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Experienced Patent Counsel

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

See all jobs

Jobs

  • Application Manager

  • Head of International Sales

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Principal Laboratory Technologist

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Experienced Patent Counsel

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge